Purpose: The present study was aimed at investigating L-asparaginase (L-ASE) activity (in plasma) and L-asparagine (L-ASN) depletion (in plasma and CSF) in children with newly diagnosed acute lymphoblastic leukemia (ALL) exposed for the first time to different L-ASE products.
Introduction
Leukemic blasts are unable to produce adequate amounts of L-asparagine (L-ASN) for their own needs and depend upon external sources. When plasma L-ASN levels fall, intracellular levels of L-ASN become markedly low, protein synthesis is inhibited and leukemic cells undergo apoptosis. L-asparaginase (L-ASE) is widely used in the treatment of leukemias and lymphomas because of its ability to reduce L-ASN plasma levels and, as a consequence, to induce cytotoxic effects in leukemic cells [1] . The native forms of L-ASE mostly used in clinical practice derive either from Erwinia chrysanthemi (Erwinia C.) or from different strains of Escherichia coli (E. coli). These products have different pharmacokinetic and antigenic properties [2] . It is believed that a reliable measurement of L-ASE activity and/or of L-ASN levels should allow to optimize L-ASE dosing schedule and to improve clinical outcome. However, data reported on L-ASN plasma depletion have been obtained in the context of various treatment schedules including different L-ASE products and methods of measurement; results are thus not complete and sometimes not easily comparable.
In a previous study we reported that sustained L-ASN depletion in plasma and cerebrospinal fluid (CSF) is usually obtained in children treated with the Erwinia C. product given intramuscularly (i.m.) at standard doses during induction [3] . Only limited information however is available on the activity of the Erwinia C. product given intravenously (i.v.) and on its comparability with the i.m. route and with other products in naive patients. The present study has been undertaken to investigate if the Erwinia C. (Erwinase®, Ipsen-Speywood Pharmaceuticals Ltd, Maidenhead, UK) or an E. coli (medac* produced by the Kyowa Hakko company, Kyogo, Japan and traded by Medac GmbH, Hamburg, Germany) product given as a first exposure and administered i.m. or i.v., are associated with different L-ASE activity in plasma and L-ASN depletion in plasma and CSF of children with newly diagnosed ALL.
Patients and methods

Patients eligibility and treatment schedule
Children diagnosed with ALL undergoing induction treatment of AIEOP ALL 95 trial were investigated in this study. The treatment schedule (BFM protocol IA) is described in Table I . Eight L-ASE doses were given to sixty-two children (30 males, 32 females, median age at diagnosis 53 months) diagnosed in the participating centers and investigated during this phase (i.e. first exposure). The administration route and the L-ASE product to be used for each patient were not specified by the study protocol and accordingly patients could receive either Erwima C or an E. coli product, i.m. or i.v., depending on the policy of the center in which they were treated. This possibility allowed the conduction of the present study. Plasma L-ASN levels and L-ASE activity were evaluated before (trough levels) the 2nd, 5th and 8th dose (i.e., day 21. 30 and 39). CSF L-ASN levels were evaluated when lumbar puncture was scheduled (i.e. day 14, 28 and 44).
Out of the 62 children, 15 received the Erwinase* (9 i.m. and 6 i.v.) and 47 children received the medac* (14 i.m. and 33 i.v.) products, respectively, at the dosage of 10,000 IU/m 2 q 3 days. Glucose, transaminase, amylase and fibrinogen levels were routinely studied at least once a week during L-ASE treatment. Major complications attributable to the use of L-ASE were also recorded.
Numbers in parentheses represent the number of determinations for each L-asparaginase dose. Each L-asparaginase activity value represents the mean ± standard deviation. The dose number indicates the dose before which the activity levels were found (trough levels). a Medac® vs. Erwinase* (i.m. or i.v): P < 0.001.
Determination of plasma L-ASE activity
A mixture of 40 ul plasma and 160 ul 0.05 M Tris-Hcl, pH 8.5 solution containing 12.5 mM L-asparagine was incubated at 37 °C for 30 min. After addition of 50 ul trichloroacetic acid 15% and centrifugation at 13,000 rpm for 10 min, 200 ul of the supernatant was added to Nessler solution (650 ul water plus 100 ul Nessler's reagent) (Nessler's reagent was obtained from Aldnch Chemical Company, Inc., Milwaukee, USA). The optical density at 405 nm was compared with an L-asparaginase standard curve between 25-600 mU/ml in human standard plasma. The units of the enzyme activity were defined as micromoles of ammonia released per minute. The coefficient of variation of the method was < 15% and the detection limit was 50 mU/ml.
Statistics
Comparison between the means of 1. L-ASE activities 2. Fibrinogen, amylase, glucose, transaminase which were found in samples obtained from patients treated with the medac 11 versus the Erwinase* product (administered either i.m. or i.v.) was performed by using the Student's r-test.
Sample collection
According to the treatment schedule, blood samples from a peripheral vein or central venous catheter were obtained just before one of the above mentioned L-ASE doses (i.e., trough levels at time intervals of three days). Samples were placed in heparinized tubes and centrifuged at 1200 rpm for 10 minutes and immediately frozen. The plasma was stored at -70 = C until analysis. CSF samples obtained when lumbar punctures were scheduled in the treatment plan, were immediately frozen and stored at -70 "C until analysis.
Determination of plasma and CSF L-ASN levels L-ASN levels in plasma and CSF were measured using an HPLC technique after column derivatization with o-phtaldialdehyde as described by Turnell and Cooper [4] .' Plasma samples from healthy volunteers were regularly tested with the samples of the patients and were ahvajs found positive. The lower limit of detection was <0.2 uM.I both for plasma and CSF. Table 2 shows plasma L-ASE activity trough levels in samples obtained three days after administration of i.m. or i.v. Erwinase 1 * or medac 1 ''. Due to the comparatively small numbers of patients and different routes of administration, different preparations and different numbers of doses studied, some subgroups became rather small. Thirty-six (out of the planned 45) plasma samples from the Erwinase" group and ninety plasma samples (out of the planned I4l) from the medac* group were available and thus analyzed for L-ASE activity levels. Mean (± SD) plasma L-ASE activity levels found in patients treated with i.m. Erwinase^ (n = 9) did not show a statistically significant difference when compared to those observed in samples of patients (n = 6) treated with the same product by the i.v. route (130.2 ± 120 mU/ml vs. 150.1 ± 176 mU/ml). Likewise, mean (±SD) plasma L-ASE activity levels found in patients treated with i.m. medac® (n = 14) were similar to those found in patients (« = 33) treated with the same product given by the i.v. route (677.9 ± 353 mU/ml vs. 552.5 ± 340 mU/ml). However, plasma medac® L-ASE activities were significantly higher in respect of plasma Erwinase® L-ASE activities (P < 0.001). The distribution of plasma enzyme activities (trough levels) in patients treated with i.m. and i.v. medac® showed that 94.5% and 90% of samples respectively had mean trough levels ^ 100 mU/ml. Conversely, in patients treated with i.m. or i.v. Erwinase® only 33% and 56% of samples respectively had mean trough levels SslOOmU/ml.
Results
Eighty-seven CSF samples (out of the planned 186) were available and were analyzed for L-ASN levels: thirty before L-ASE treatment start (i.e., day 14), thirtyfive during L-ASE treatment (i.e., day 28, one day after the 4th dose of L-ASE) and twenty-two after L-ASE treatment (i.e., day 44, five days after the 8th dose of L-ASE). CSF L-ASN levels measured before L-ASE treatment start were comprised between 3.1 and 14.25 uM/1 (no patient had CSF L-ASN levels below the detection limit); interestingly, CSF L-ASN levels measured during or after L-ASE treatment were under the detection limit in all samples. The same results were observed when plasma L-ASN levels were evaluated. In fact, in the 36 samples obtained from the 15 patients who received the Erwinase® product (9 i.m. and 6 i.v.) and in the 90 samples obtained from the 47 patients who received the medac® product (14 i.m. and 33 i.v.), plasma L-ASN levels were always below the limit of detection, independently of the product, of the administration route and of L-ASE activity levels (e.g., L-ASN levels were below 0.2 uM/1 also in the 11 samples -i.e., 30.5% of all samples of the Erwinase® group -which had L-ASE trough activity levels < 50 mU/ml).
All patients completed the planned L-ASE schedule without major complications. Summarizing all measurements of routine laboratory tests performed to monitor, in the two groups of patients, the toxicity related to the use of L-ASE, only a significant decrease (P < 0.0001) in the mean fibrinogen values were found in the samples (n = 107) obtained from the 47 patients of the medac* group (mean 70 mg/dl, SD ± 26.1) in respect of the samples (n = 35) obtained from the 13 patients of the Erwinase® group (mean 115 mg/dl, SD ± 41.6). Mean values of the other parameters (i.e., glucose, amylase and transaminase) evaluated in the two groups were superimposable (data not shown, P -NS). None of the investigated patients presented with life-threatening complications attributable to L-ASE therapy. Discussion L-ASE has been widely used in the treatment of ALL and lymphomas [5] . Its administration unbalances leukemic cell protein synthesis catalysing the hydrolysis of L-ASN to aspartic acid and ammonia. Maximal antileukemic effect is mainly believed to happen when a deep and long-lasting plasma L-ASN depletion is obtained [2, 6] . L-ASE is however able to deplete the serum also from glutamine; this phenomenon has been proposed as an additional mechanism for its therapeutic and toxic effects [7] . Most of the clinical and laboratory data available on the use of L-ASE have been reported from patients treated in front-line or relapse chemotherapy protocols with the Bayer (Crasnitin®) or MSD (Elspar®) E. coli products; pharmacological data on the Erwinia C. product have been mostly obtained from patients presenting with hypersensitivity reactions to E. coli products [8] or undergoing Erwinia C. L-ASE treatment as a second exposure [9] ; in these patients an inactivation due to cross-reactive neutralizing antibodies cannot be excluded.
In front-line treatment schedules [2] Erwinase® has been used at the same dosage and schedule of other E. coli products [10, 11] in spite of its well-known shorter half-life, and has been reported to have a lower risk of side effects but similar clinical efficacy (historical comparisons) to Crasnitin® [12, 13] . In the last decade other products, such as the medac® L-ASE derived from different E. coli strains, displaying very different clinical and biological effects, have been introduced in the market, renewing the attention for studies on L-ASE [14, 15] . Comparative pharmacokinetic, pharmacodynamic and clinical studies have shown that not only the dosage, the schedule and the chemotherapy agents concomitantly administered [16] but also the product used [12] may significantly affect the biological effects of L-ASE.
The present study was undertaken to investigate if two L-ASE products (Erwinase® and Medac®), displayed similar biological effects in ALL children treated with conventional doses, i.m. or i.v., during induction treatment (first exposure). In this study the probability of neutralizing antibodies interference [17, 18] is considered to be very low (this was the first exposure to the drug) and thus should not have affected the results reported in this paper.
Plasma and CSF L-ASN levels remained below the detection limit in all patients, independently of the product and of the administration route used. Due to the inter-individual variability and the relatively small size of the groups investigated, L-ASE activity levels resulted in huge variances and wide ranges; the L-ASE activity levels were however clearly and significantly higher in the medac 1 *' group in respect of the Erwinase' 5 ' group. The findings on the medac 14 ' E. coli product are in good agreement with data published by Boos et al., who found that L-ASE activity levels were beyond that needed to induce an adequate L-ASN depletion and thus potentially at increased risk of adverse effects; the dose of the medac L-ASE was accordingly halved to 5,000 IU/m 2 in the induction schedule of the ALL/ NHL-BFM trials [19] , and in the current AIEOP ALL 95 study too. Very recently it has been reported that the use of an L-ASE (Leunase®, Kyowa Hakko, Kyogo, Japan) product, having identical properties of the medac® product, used every other day for 9 doses at the dosage of 10,000 IU/m 2 in the context of a different chemotherapy induction schedule (in respect of the AIEOP ALL 95), was poorly tolerated and resulted in excessive toxicity [20] .
Pharmacokinetic data published in the early 1980s by Riccardi et al. reported that complete L-ASN depletion in the plasma and in the CSF were obtained in patients treated with E. coli L-ASE when enzyme plasma activity levels were at least 100 mU/ml [21] . In 1996, Boos et al. have found that in patients undergoing a first exposure to the Crasnitin® product, median L-ASE trough activity levels of 74 mU/ml were sufficient to ensure the desired L-ASN depletion in most patients [22] . Findings of the present study suggest that L-ASN depletion can be obtained also with lower L-ASE activity levels.
Due to the 'silent inactivation' phenomenon and to large interindividual pharmacological differences, it might be difficult however, in the case of a second or subsequent exposure to the drug, to reach the above mentioned activity levels by using the same dosage/ schedule adopted for the first exposure. To overcome this problem it has been suggested to increase the dosage of the drug and/or to use a different schedule [8] . In a recent study Woo et al. did not find a significant decrease in the proportion of children with CSF L-ASN depletion undergoing a course of three-times-weekly standard-dose (10,000 IU/m 2 ) i.m. E. coli L-ASE (Elspar®, Merck & Co Inc, West Point, Pennsylvania, USA) as first (newly diagnosed children) or second (relapsed patients) exposure; in this latter group however nine L-ASE doses were used instead of the six given in the former [23] .
Our data show that the i.m. or the i.v. administration routes provide equivalent activity levels, for both the Erwinase® and the medac® products, suggesting that the administration route used during the first exposure to L-ASE products should not affect the clinical efficacy. From these data it seems also that the conventional schedule of 10,000 IU/m 2 q 3 days during the first exposure to Erwinase® may be appropriate, whereas this dosage may be reduced when the medac® product is used.
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Note
1 In a previous study we have determined L-ASN levels in plasma and CSF in children treated with Erwinia C. L-ASE [3] . In that study plasma was immediately deproteinized after sampling and L-ASN levels were determined both in the whole blood and in the red blood cells and by difference in the plasma. The experiment conducted to reveal inhibitory activity to L-ASE, for which deproteinization was not done, showed however that L-ASN levels in samples obtained from patients in which no depletion was observed, were still high after a prolonged freezing. The same experiment showed also that in samples in which L-ASN depletion was found L-ASE activity was invariably present. These data suggest that L-ASN levels are strictly correlated to plasma L-ASE activity and that deproteinization may not be necessarily used to measure plasma L-ASN levels, at least when L-ASE activity is measured too. A stability test performed in our laboratory (data not reported) showed also that L-ASE added to plasma obtained from healthy volunteers maintains its activity unchanged (stable) for long time in frozen samples. Considering that in the present study L-ASE activity was measured too, L-ASN levels in plasma have been determined directly (i.e , without deproteinization).
